01—Abstract
Summary
Summary of the 8-K filed September 16, 2025. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc. (DXCM) has announced that its Chief Executive Officer and Chairman of the Board, Kevin R.
Sayer, is taking a temporary medical leave of absence, effective September 14, 2025. This development necessitates a temporary leadership transition to ensure continuity of operations and strategic direction. In response, the Board of Directors has appointed Jacob S.
Leach, currently President and Chief Operating Officer, to serve as the interim principal executive officer. Additionally, Mark Foletta, the Lead Independent Director, has been appointed as the interim Chairman of the Board.
Investors should note that neither Mr. Leach nor Mr. Foletta will receive additional compensation for these interim roles, signaling a commitment to stable governance during this period. The company has emphasized that Mr. Leach's appointment is not subject to any specific arrangements or understandings with other parties and that he has no material interests in any reportable transactions.
02—Key points
Key Highlights
- CEO Kevin R. Sayer has begun a temporary medical leave of absence effective September 14, 2025.
- Jacob S. Leach, President and COO, has been appointed interim principal executive officer.
- Mark Foletta, Lead Independent Director, has been appointed interim Chairman of the Board.
- The interim appointments are effective September 14, 2025.
- No additional compensation will be provided to Messrs. Leach and Foletta for their interim roles.
- The company has provided assurances regarding Mr. Leach's lack of pre-arranged selection criteria and material interests in disclosed transactions.
03—Questions
Frequently Asked Questions
What is the primary reason for this 8-K filing?
This 8-K filing is primarily to announce that the CEO, Kevin R. Sayer, is taking a temporary medical leave of absence and to detail the interim leadership appointments made by the Board of Directors to ensure continued operations.
Who is taking over the CEO responsibilities in the interim?
Jacob S. Leach, who currently holds the positions of President and Chief Operating Officer, has been appointed as the interim principal executive officer.
Will the interim leaders receive extra pay for these new roles?
No, the filing explicitly states that neither Jacob S. Leach nor Mark Foletta will receive any additional compensation in connection with their respective interim appointments.
When is Kevin R. Sayer expected to return?
The filing states that Mr. Sayer is taking a 'temporary' medical leave of absence, but it does not provide a specific timeline for his return. Further updates may be provided in future filings or company communications.
04—Continue